(S)-2-[3-(6-Hydroxy-naphthalen-1-yl)-ureido]-pentanedioic acid 5-tert-butyl ester | 189393-60-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-[3-(6-Hydroxy-naphthalen-1-yl)-ureido]-pentanedioic acid 5-tert-butyl ester
• 英文别名: (2S)-2-[(6-hydroxynaphthalen-1-yl)carbamoylamino]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid
• CAS: 189393-60-0
• 化学式: C₂₀H₂₄N₂O₆
• 分子量: 388.42
• InChiKey: FIPOBUSYTFFYCF-INIZCTEOSA-N

物化性质

• 沸点：
  613.9±55.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-2-[3-(6-Hydroxy-naphthalen-1-yl)-ureido]-pentanedioic acid 5-tert-butyl ester 在 N-甲基吗啉 、 四氮唑 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Design, Synthesis, and Cocrystal Structure of a Nonpeptide Src SH2 Domain Ligand

  摘要：

  The specific association of an SH2 domain with a phosphotyrosine (pTyr)-containing sequence of another protein precipitates a cascade of intracellular molecular interactions (signals) which effect a wide range of intracellular processes. The nonreceptor tyrosine kinase Src, which has been associated with breast cancer and osteoporosis, contains an SH2 domain. Inhibition of Src SH2-phosphoprotein interactions by small. molecules will aid biological proof-of-concept studies which may lead to the development of novel therapeutic agents. Structure-based design efforts have focused on reducing the size and charge of Src SH2 ligands while increasing their ability to penetrate cells and reach the intracellular Src SH2 domain target. In this report we describe the synthesis, binding affinity, and Src SH2 cocrystal structure of a small, novel, nonpeptide, urea-containing SH2 domain ligand.

  DOI：

  10.1021/jm970402q
• 作为产物：
  描述：

  在 氢氧化钾 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 48.0h， 生成 (S)-2-[3-(6-Hydroxy-naphthalen-1-yl)-ureido]-pentanedioic acid 5-tert-butyl ester
  参考文献：
  名称：

  Design, Synthesis, and Cocrystal Structure of a Nonpeptide Src SH2 Domain Ligand

  摘要：

  The specific association of an SH2 domain with a phosphotyrosine (pTyr)-containing sequence of another protein precipitates a cascade of intracellular molecular interactions (signals) which effect a wide range of intracellular processes. The nonreceptor tyrosine kinase Src, which has been associated with breast cancer and osteoporosis, contains an SH2 domain. Inhibition of Src SH2-phosphoprotein interactions by small. molecules will aid biological proof-of-concept studies which may lead to the development of novel therapeutic agents. Structure-based design efforts have focused on reducing the size and charge of Src SH2 ligands while increasing their ability to penetrate cells and reach the intracellular Src SH2 domain target. In this report we describe the synthesis, binding affinity, and Src SH2 cocrystal structure of a small, novel, nonpeptide, urea-containing SH2 domain ligand.

  DOI：

  10.1021/jm970402q

文献信息

• Compounds, compositions and methods for inhibiting the binding of
  申请人：Warner-Lambert Company

  公开号：US05922697A1

  公开（公告）日：1999-07-13

  The present invention provides compounds that inhibit the binding of proteins containing an SH2 domain to cognate phosphorylated proteins. The invention also provides pharmaceutical compositions containing the compounds and methods of inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins.

  本发明提供了抑制含有SH2结构域蛋白与同源磷酸化蛋白结合的化合物。该发明还提供了含有这些化合物的药物组合物以及抑制含有SH2结构域蛋白与同源磷酸化蛋白结合的方法。